Table 1.22 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2016^a By Age at Prevalence

Site/Sex	Age at Prevalence									
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+	
All Sites										
Males	7,046,820	19,013	45,658	92,312	168,663	324,888	900,095	1,901,064	3,595,127	
Females	8,292,168	17,282	38,768	93,009	252,052	631,369	1,452,263	2,179,010	3,628,415	
Oral Cavity & Pharynx										
Males	250,059	79	483	1,435	3,554	12,626	49,283	84,123	98,476	
Females	120,250	80	486	1,591	3,870	8,272	20,688	31,925	53,339	
Esophagus										
Males	35,559	0	0	29	183	903	4,460	11,824	18,160	
Females	10,918	0	0	11	54	242	1,320	3,146	6,144	
Stomach										
Males	64,837	0	24	160	789	2,727	9,103	17,395	34,640	
Females	48,217	0	34	215	859	2,676	7,066	11,599	25,768	
Colon & Rectum										
Males	661,406	19	310	1,521	6,867	26,306	95,856	171,638	358,889	
Females	663,516	39	358	1,832	6,831	25,137	85,953	146,080	397,285	
Liver & Intrahep										
Males	57,099	624	769	529	434	1,690	10,569	26,699	15,787	
Females	25,982	541	654	392	562	1,249	3,991	9,069	9,525	
Pancreas										
Males	36,418	8	58	120	525	1,740	5,902	11,974	16,091	
Females	37,136	12	70	338	716	2,183	6,294	10,710	16,812	
Larynx										
Males	78,929	6	8	102	246	1,565	8,956	22,799	45,246	
Females	17,422	0	16	16	151	658	3,099	5,295	8,188	
Lung & Bronchus										
Males	239,856	51	127	370	1,223	4,483	23,185	66,309	144,108	
Females	298,387	42	71	411	1,456	5,877	32,254	76,338	181,938	
Melanoma of the Skin										
Males	611,158	58	530	4,277	16,027	39,516	98,628	166,460	285,663	
Females	584,451	109	657	8,033	31,954	66,800	124,763	146,768	205,367	

U.S. 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 areas not including the Alaska Natives Registry (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, Rural Georgia, San Jose-Monterey, and Los Angeles) and 1/1/2016 U.S. population estimates based on the average of 2015 and 2016 population estimates from the U.S. Bureau of the Census.

Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years. Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

а

b c

Table 1.22 - continued U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2016^a By Age at Prevalence

Site/Sex	Age at Prevalence									
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+	
Descart										
Breast	10 400	0	0	4	125	504	0 000	4 070	11 00	
Males Females	19,496	0 16	0 25	2 276	135	584	2,200	4,872	11,703	
Females	3,477,866	10	25	3,276	39,571	207,774	602,250	975,728	1,649,227	
Cervix										
Females	289,696	0	42	1,803	14,401	41,426	66,591	72,523	92,910	
Corpus & Uterus, NOS										
Females	772,245	8	14	867	7,585	28,997	101,642	228,398	404,73	
Ovary ^d										
Females	229,875	106	1,124	4,479	8,509	19,167	46,532	64,680	85,279	
Prostate										
Males	3,110,403	24	52	54	206	14,018	217,572	865,480	2,012,997	
Urinary Bladder										
Males	525,713	60	99	541	2,145	8,784	39,848	120,226	354,01	
Females	173,737	49	64	251	979	3,027	13,312	36,306	119,749	
Kidney & Renal Pelvis										
Males	326,154	1,538	2,140	2,609	9,271	21,911	54,924	92,324	141,43	
Females	207,050	1,706	2,575	3,132	6,768	14,900	33,535	52,972	91,463	
Hodgkin Lymphoma										
Males	108,576	179	2,567	9,822	15,519	21,451	26,921	19,909	12,20	
Females	102,397	70	1,843	8,849	16,460	21,101	24,748	17,379	11,94	
Non-Hodgkin Lymphoma										
Males	367,558	900	4,029	8,311	13,996	27,628	61,422	94,982	156,29	
Females	327,146	521	1,769	4,696	10,164	21,105	48,512	82,379	157,99	
Myeloma										
Males	72,999	0	8	83	680	3,390	11,695	22,552	34,59	
Females	58,392	3	9	60	426	2,610	8,912	17,672	28,69	
Leukemia										
Males	235,556	6,996	15,050	16,790	12,272	17,182	30,974	51,848	84,44	
Females	179,217	6,251	11,682	13,694	10,821	13,891	22,189	34,672	66,01	
Acute Lymphocytic Leuk										
Males	52,176	5,892	12,608	13,226	8,345	6,762	3,097	1,536	71	
Females	43,589	5,242	9,971	10,290	7,475	5,610	2,594	1,532	87	

U.S. 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 areas not including the Alaska Natives Registry (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, Rural Georgia, San Jose-Monterey, and Los Angeles) and 1/1/2016 U.S. population estimates based on the average of 2015 and 2016 population estimates from the U.S. Bureau of the Census.

Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years. Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). b С

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

а